Temozolomide

TargetMol
Product Code: TAR-T1178
Supplier: TargetMol
CodeSizePrice
TAR-T1178-10mg10mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1178-1mL1 mL * 10 mM (in DMSO)£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1178-25mg25mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1178-50mg50mg£142.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1178-100mg100mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1178-200mg200mg£174.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1178-500mg500mg£206.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1178-1g1g£270.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Temozolomide is a DNA alkylating agent interfering with DNA replication.
CAS:
85622-93-1
Formula:
C6H6N6O2
Molecular Weight:
194.154
Pathway:
DNA Damage/DNA Repair; Apoptosis; Autophagy; Cell Cycle/Checkpoint
Purity:
0.9987
SMILES:
Cn1nnc2c(ncn2c1=O)C(N)=O
Target:
Apoptosis; DNA Alkylator/Crosslinker; DNA/RNA Synthesis; Autophagy

References

1. Marchesi F, et al. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res. 2007 Oct;56(4):275-87. 2. Perazzoli G, et al. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS One. 2015 Oct 8;10(10):e0140131. 3. Sun S, et al. Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide. J Neurooncol. 2012 Sep;109(3):467-75. 4. Tentori L, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002 Mar 15;99(6):2241-4. 5. Daniel RA, et al. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. 6. Zhang B, Xu C, Liu J, et al. Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients[J]. Aging (Albany NY). 2021, 13(6): 9085. 7. Herbener V J, Burster T, Goreth A, et al. Considering the Experimental use of Temozolomide in Glioblastoma Research[J]. Biomedicines. 2020, 8(6): 151.